Alnylam Pharmaceuticals, Inc.
Investor Relations Department
300 Third Street
Cambridge, MA 02142
United States

Visit IR website
Sign-up for e-mail alerts

| NASDAQ: ALNY [1] | |
|---|---|
| Last Trade: | 51.09 |
| Trade Time: | 10:31 AM ET 03.30.2017 |
| Change: | -1.74 (3.294%) |
| Day Range | 50.79 - 52.81 |
| 52-Week Range | 31.38 - 80.11 |
| Volume | 107,777 |
| Market Cap. ($M) | 4,396.295 |
| Shares Out (M) | 86.050 |

[1] The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics as genetic medicines, including programs as part of the company's "Alnylam 5x15™" product strategy. Alnylam's genetic medicine programs are RNAi therapeutics directed toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers.

… (more)

## Stock Performance

## Press Releases [ View all ]

*03.28.2017*
Alnylam to Webcast Presentation at 16th Annual Needham Healthcare Conference

*03.17.2017*
The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran

*03.01.2017*
Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias

*02.28.2017*
Alnylam Acknowledges Rare Disease Day by Highlighting Services to Aid in Rare Disease Diagnosis

*02.27.2017*
Alnylam to Webcast Presentations at Upcoming March Investor Conferences

## Events [ View all ]

*04.05.2017 11:20 AM ET*
16th Annual Needham Healthcare Conference

## Financials [ View all ]

Third Quarter Financial Results

*02.15.2017*
Annual Report (10-K)

*03.17.2017*
Definitive Proxy Statement

*11.03.2016*
Quarterly Report (10-Q)

*08.04.2016*
Quarterly Report (10-Q)

*05.04.2016*
Quarterly Report (10-Q)

Nasdaq